Lancet Oncol 2020 Jan
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Related Questions
New answer by Medical Oncologist at City of Hope (June 23, 2021)
While thrombosis/thromboembolic events are considered a class effect amongst several VEGF/TKIs, and venous and/or arterial thromboembolic events have been seen in 2-5% of pati...
Patient has progression of liver metastases while on pembrolzumab/axitinib. ECOG PS 1 and limited comorbidities.
New answer by Medical Oncologist at Dana-Farber Cancer Institute (October 20, 2021)
Treatment following progression on IO/TKI depends on the regimen chosen in the front line. We have pursued retrospective analysis showing that cabozantinib maintains efficacy ...